Endometrial hyperplasia
Also known as: Uterine endometrial hyperplasia, Endometrial hyperplasia without atypia, Atypical endometrial hyperplasia, Endometrial intraepithelial neoplasia (EIN)
Endometrial hyperplasia is the excessive proliferation of the uterine endometrium, primarily resulting from oestrogen stimulation unopposed by progesterone. Histological classification distinguishes between hyperplasia without atypia and atypical hyperplasia (endometrial intraepithelial neoplasia, or EIN). Due to the significant risk of progression to endometrial adenocarcinoma associated with atypical hyperplasia, specialist gynaecological management is mandatory. Conventional interventions include progestogen therapy, serial endometrial biopsies, or hysterectomy, depending on histopathology and reproductive objectives. TCM serves solely as adjunctive symptomatic support; it is not a substitute for medical surveillance and has no established role in inducing histological regression. Cited evidence includes no clinical trials for endometrial hyperplasia. One small trial in patients with PCOS noted transient menstrual alterations, one record is a study protocol, and both the malignancy review and animal research fail to confirm clinical efficacy for this condition.
Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.
Lifestyle & Diet
- •Maintain a comprehensive bleeding diary recording dates, estimated flow volume, presence of clots, pain intensity, and dizziness for clinical review.
- •Adhere strictly to prescribed pharmacological regimens and attend all scheduled gynaecological consultations and endometrial biopsies, irrespective of symptomatic resolution.
- •Emphasise sustainable physical activity, balanced nutritional intake, and metabolic support where PCOS or weight-related risks are present; avoid blame or restrictive dietary practices.
- •Prioritise consistent sleep hygiene and disclose all herbal medicines, nutritional supplements, and exogenous hormonal products to the medical team prior to initiation.
Cautions & Contraindications
- •Do not use acupuncture or herbs instead of biopsy, progestogen therapy, indicated surgery or oncology assessment. The supplied malignancy review does not establish that TCM treats hyperplasia or prevents cancer.[]
- •Do not interpret more frequent periods as proof of ovulation, endometrial protection or histological regression. The small PCOS trial measured menstrual outcomes, and the second PCOS record is a protocol without efficacy results.[,]
- •Defer elective needling during haemodynamic instability, severe symptomatic anaemia or unexplained acute pelvic symptoms. Check pregnancy status where relevant and use pregnancy-specific precautions. These are general safety measures; the pilot trial's absence of serious adverse events does not establish safety in these populations.[]
- •Do not infer human reproductive safety, absence of oestrogenic effects or hyperplasia benefit from the Moutan cortex rat and cell findings. Herbal use with hormonal therapy, during pregnancy or in suspected malignancy requires individual review.[]
When to reassess or seek care again
Review adjunctive care after 2–4 weeks using bleeding days, pad use, pain and fatigue scores, sleep disruption and adverse effects. Check haemoglobin and iron status through the medical team when indicated. Stop or modify adjunctive care if symptoms worsen or there is no meaningful symptom benefit after 4–6 weeks. New postmenopausal bleeding, persistent increased bleeding or any atypia/EIN result requires prompt specialist review; instability requires emergency care. Histological response must be assessed by the gynaecology team on its scheduled sampling pathway, not by tongue, pulse, ultrasound alone or menstrual regularity.
Explore more diseases
Sources & Further Reading
Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.
- International journal of women's health · 2026
- Frontiers in endocrinology · 2026
- Frontiers in oncology · 2025
- Journal of ethnopharmacology · 2026
Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.
